The rise of antibiotic resistance is an increasingly serious threat in every corner of the world. The development of new antibiotics, especially with new modes of action, is imperative to treat microbial-caused infectious disease. Transcription factor NusA is highly conserved, unique and indispensable to bacteria, but transcription is an underutilised target in antibiotic development and there is not an antibiotic acting on NusA. Therefore the development of lead molecules inhibiting NusA activity represents a promising opportunity to develop a new class of antibiotics.
We aim to design a new class of antibiotics specifically targeting the interaction of the essential transcription factor NusA and its binding region on RNA polymerase.
This research will provide the first high-resolution structure of the interaction of bacterial RNA polymerase with the essential transcription factor NusA, and will guide development of lead molecules for drug design.